Filing Flows › Health Care › Invo Fertility (IVF)
Invo Fertility (IVF) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Invo Fertility (IVF) Q2 2026 earnings results →
Q2 2026 Revenue up 17% year over year to $2.2M · 41¢ of every $1 of revenue kept as net profit · operating margin -59.3%
Invo Fertility made $2.2M in Q2 2026 (+17% Y/Y): Clinic Revenue $2.2M, Product $8K. Operating margin -59.3%, net earnings $889K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $2.2M in Q2 2026, up 17% year over year and up 8% from the previous quarter. Clinic Revenue was the largest line at 100% of revenue. Clinic Revenue added $336K year over year (up 18%), 108% of the total change. Product declined 76%.
Operating costs exceeded revenue by $1.3M, an operating margin of -59.3%. Total costs fell 29% while revenue rose 17%. The fastest-growing cost line was Cost of revenue (+1864%). Net earnings were $889K. The effective tax rate was 5.9%. Non-operating items added $2.2M, 236% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.1M. Non-cash charges added back $146K of depreciation and amortization. Working capital and other items used $2.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $2.2M | +17% | -59.3% | $889K | −$1.1M |
| Q1 2026 | 10-Q | Jun 22, 2026 | $2.0M | +23% | -78.9% | −$5.5M | −$1.9M |
| Q4 2025 | 10-K | Jun 2, 2026 | $1.6M | -6% | -89.2% | $1.1M | $25K |
| Q3 2025 | 10-Q | Nov 17, 2025 | $1.8M | +23% | -93.1% | −$1.7M | −$1.8M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $1.9M | +2% | -160.4% | −$6.8M | −$1.7M |
| Q1 2025 | 10-Q | May 20, 2025 | $1.6M | +4% | n/m | −$17.4M | −$3.5M |
| Q4 2024 | 10-K | Apr 30, 2025 | $1.7M | +22% | -235.8% | $4.6M | −$617K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Invo Fertility
This Annual Report on Form 10-K should be read together and in connection with the other reports that have been filed by us with the SEC for a comprehensive description of our financial condition and operating results. In the interest of disclosure, we have included in this Form 10-K certain material events and developments that have taken place through the date of filing of this Form 10-K with the SEC. In this Annual Report on Form 10-K, INVO Fertility, Inc., (INVO Fertility, Inc., together with its subsidiaries, is referred to in this document as “we”, “us”, “INVO Fertility”, “INVO”, or the “Company”), incorporates by reference certain information from parts of other documents filed with the SEC. The SEC allows us to disclose important information by referring to it in that manner. Please refer to all such information when reading this Annual Report on Form 10-K.
In its own words, from its 10-K, filed Jun 2, 2026.
Invo Fertility against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +17% against the peers' median +5%. Operating margin: -59.3% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IVF Invo Fertility | Q2 2026 | $2.2M | +17% | -59.3% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Invo Fertility 10-Q on SEC EDGAR · CIK 1417926 · Surgical & Medical Instruments & Apparatus
13F: who owns IVF and who is buying
More on IVF
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results